AstraZeneca has become the latest big pharma company to devote new cash to its US manufacturing muscle this year as it ...

President Joe Biden’s career-defining victories over Big Pharma — reforming Medicare to lower prices and capping inhaler costs for millions of Americans with lung disease — are facing an ...

UK-based global pharma company AstraZeneca and US consumer products company Honeywell have announced a partnership to build a new "next generation" inhaler with a propellant that reduces Global ...

Though prescribing climate-friendly inhalers is environmentally sound, some experts warn certain patients may be overlooked.

Under the leadership of Pam Cheng, the company’s chief sustainability officer, Breztri may soon be released in a new package ...

In good news for those averse to injections, GLP-1 agonist medication is a step closer to being offered in oral pill form, ...

Chinese authorities detained AstraZeneca employees amid a probe into data privacy breaches and unlicensed drug sales, stock ...

Respiratory Inhaler Devices MarketThe global respiratory inhaler devices market, valued at USD 37,258.5 million in 2023, is projected to grow at a compound annual growth rate (CAGR) of 4.90%, reaching ...

AstraZeneca to Cap Out-of-pocket Inhaler Costs in US, Following Rival Boehringer's Move Drugmaker AstraZeneca said on Monday it would cap out-of-pocket costs for its inhaled respiratory products ...

A spokesman said the president of its China business Leon Wang is co-operating with an investigation by Ch.inese authorities.

AstraZeneca stock tumbles as Chinese probe widens, implicating executives in insurance fraud and drug import violations ...